Compare ARLP & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARLP | TARS |
|---|---|---|
| Founded | 1971 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.4B |
| IPO Year | 1999 | 2020 |
| Metric | ARLP | TARS |
|---|---|---|
| Price | $25.22 | $76.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $32.33 | ★ $103.44 |
| AVG Volume (30 Days) | 311.8K | ★ 857.6K |
| Earning Date | 10-26-2026 | 11-03-2026 |
| Dividend Yield | ★ 9.57% | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,002,857,000.00 | $451,360,000.00 |
| Revenue This Year | $2.94 | $64.28 |
| Revenue Next Year | $3.94 | $26.15 |
| P/E Ratio | $10.68 | ★ N/A |
| Revenue Growth | 11.50 | ★ 146.71 |
| 52 Week Low | $23.01 | $53.89 |
| 52 Week High | $29.45 | $91.53 |
| Indicator | ARLP | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 45.50 | 58.05 |
| Support Level | $23.96 | $67.49 |
| Resistance Level | $25.33 | $76.79 |
| Average True Range (ATR) | 0.59 | 3.88 |
| MACD | -0.15 | 0.48 |
| Stochastic Oscillator | 38.10 | 88.33 |
Alliance Resource Partners LP operates as a coal mining company based in the United States. It has four segments: Illinois Basin, Appalachia, Oil & Gas Royalties, and Coal Royalties. The Illinois Basin comprises underground mining complexes in Illinois, Indiana, Kentucky, Maryland, and West Virginia. The Appalachia segment comprises the Mettiki mining complex, the Tunnel Ridge mining complex, and the MC Mining complex. The Oil & Gas Royalties has oil & gas mineral interests held by AR Midland and AllDale I & II, and includes Alliance Minerals' equity interests in both AllDale III and Cavalier Minerals. The Coal Royalties have included coal mineral reserves and resources owned or leased by Alliance Resource Properties.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.